Date: 2015-09-01
Type of information: Nomination
Compound:
Company: BergenBio (Norway)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 1, 2015, BerGenBio, an oncology biopharmaceutical company, announced that it has appointed Hilde Furberg and Dr Stener Kvinnsland as Non-Executive Directors to its Board of Directors, effective immediately.
Hilde Furberg has over 30 years of experience in pharma and biotech and is currently Senior Vice President Rare Diseases EMEA at Genzyme, a Sanofi company. Previously her role was Vice President and General Manager of Nordic Benelux and Nordic General Manager at Genzyme. Prior to joining Genzyme, Ms Furberg was Managing Director and part-owner of Pharmalink A/S and held a number of roles at Baxter including Managing Director, Sweden. She is currently a board member at Pharmalink AB and has held board positions at Algeta ASA, Clavis, Pronova and Probi AB.
Dr Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan.
Financial terms:
Latest news:
